Scientists find new ways to convert inhibitors into degraders, paving the way for future drug discoveries 11 Apr 2024 Researchers have discovered ways to convert inhibitor-style targeted cancer drugs into small molecules known as degraders, which help destroy cancer-promoting proteins in cells. Find out more Show/Hide
ICR and Merck renew strategic alliance in discovery and development of innovative new small-molecule cancer drugs 22 Sep 2023 The Institute of Cancer Research, London, and science and technology company Merck have renewed their strategic alliance in the discovery and development of new cancer drugs. Find out more Show/Hide
‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide
ICR Discovery Club celebrates the second anniversary of the Centre for Cancer Drug Discovery 07 Nov 2022
The Princess Royal officially opens pioneering centre for 'Darwinian' cancer drug discovery 08 Oct 2021